Prevention of recurrence after resection of hepatocellular carcinoma: A daunting challenge

Hepatology

Volumn 54, Issue 3, 2011, Pages 757-759

  Poon, Ronnie T P ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC AGENT; FARNOQUINONE; INTERFERON; RADIOACTIVE IODINE; RETINOID; SORAFENIB;

ABLATION THERAPY; ADOPTIVE IMMUNOTHERAPY; ANTINEOPLASTIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER INHIBITION; CANCER PREVENTION; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; DISEASE FREE SURVIVAL; EDITORIAL; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MOLECULARLY TARGETED THERAPY; OSTEOLYSIS; PERIOPERATIVE PERIOD; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; SURGICAL MORTALITY; SURGICAL TECHNIQUE;

CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; NEOPLASM RECURRENCE, LOCAL; VITAMIN K 2; VITAMINS;

EID: 80052002437     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24569     Document Type: Editorial

References (20)

1. Fan ST, Mau Lo C, Poon RT, Yeung C, Leung Liu C, Yuen WK, et al. Continuous improvement of survival outcomes of resection of hepatocellular carcinoma: a 20-year experience. Ann Surg 2011; 253: 745-758.
2. Poon RT, Fan ST, Wong J. Risk factors, prevention, and management of recurrence after resection of hepatocellular carcinoma. Ann Surg 2000; 232: 10-24.
3. Wang XQ, Ongkeko WM, Chen L, Yang ZF, Lu P, Chen KK, et al. Octamer 4 (Oct4) mediates chemotherapeutic drug resistance in liver cancer cells through a potential Oct4-AKT-ATP-binding cassette G2 pathway. HEPATOLOGY 2010; 52: 528-539.
4. Sun HC, Tang ZY. Preventive treatments for recurrence after curative resection of hepatocellular carcinoma-a literature review of randomized control trials. World J Gastroenterol 2003; 9: 635-640.
5. Lau WY, Leung TW, Ho SKW, Chan M, Machin D, Lau J, et al. Adjuvant intra-arterial lipiodol iodine-131 for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet 1999; 353: 797-801.
6. Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 2000; 356: 802-807.
7. Muto Y, Moriwaki H, Ninomiya M, Adachi S, Saito A, Takasaki KT, et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med 1996; 334: 1561-1567.
8. Okita K, Matsui O, Kumada H, Tanaka K, Kaneko S, Moriwaki H, et al. Effect of peretinoin on recurrence of hepatocellular carcinoma (HCC): results of a phase II/III randomized placebo-controlled trial. J Clin Oncol 2010; 28(suppl; abstr 4024): 15.
9. Breitenstein S, Dimitroulis D, Petrowsky H, Puhan MA, Müllhaupt B, Clavien PA. Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis. Br J Surg. 2009; 96: 975-981.
10. Singal AK, Freeman DH Jr., Anand BS. Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma. Aliment Pharmacol Ther 2010; 32: 851-858.
11. Lo CM, Liu CL, Chan SC, Lam CM, Poon RT, Ng IO, et al. A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg 2007; 245: 831-842.
12. Poon RT, Fan ST, Ng IO, Lo CM, Liu CL, Wong J. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 2000; 89: 500-507.
13. Yoshida H, Shiratori, Y, Kudo M, Shiina S, Mizuta T, Kojiro M, et al. Effect of Vitamin K2 on the recurrence of hepatocellular carcinoma. A randomized, placebo-controlled, double-blind phase II/III study. HEPATOLOGY 2011; 54: 532-540.
14. Ozaki I, Zhang H, Mizuta T, Ide Y, Eguchi Y, Yasutake T, et al. Menatetrenone, a vitamin K2 analogue, inhibits hepatocellular carcinoma cell growth by suppressing cyclin D1 expression through inhibition of nuclear factor κB activation. Clin Cancer Res 2007; 13: 2236-2245.
15. Kuriyama S, Hitomi M, Yoshiji H, Nonomura T, Tsujimoto T, Mitoro A. Vitamins K2, K3, and K5 exert in vivo antitumor effects on hepatocellular carcinoma by regulating the expression of G1 phase-related cell cycle molecules. Int J Oncol 2005; 27: 505-511.
16. Habu D, Shiomi S, Tamori A, Takeda T, Tanaka T, Kubo S, et al. Role of vitamin K2 in the development of hepatocellular carcinoma in women with viral cirrhosis of the liver. JAMA 2004; 292: 358-361.
17. Hotta N, Ayada M, Sato K, Ishikawa T, Okumura A, Matsumoto E, et al. Effect of vitamin K2 on the recurrence in patients with hepatocellular carcinoma. Hepatogastroenterology 2007; 54: 2073-2077.
18. Kakizaki S, Sohara N, Sato K, Suzuki H, Yanagisawa M, Nakajima H, et al. Preventive effects of vitamin K on recurrent disease in patients with hepatocellular carcinoma arising from hepatitis C viral infection. J Gastroenterol Hepatol 2007; 22: 518-522.
19. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
20. Liu CJ, Lee PH, Lin DY, Wu CC, Jeng LB, Lin PW, et al. Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosage. J Hepatol 2009; 50: 958-968.